Prostate Cancer in 2021: Novelties in Prognostic and Therapeutic Biomarker Evaluation.
DNA damage repair pathway
DNA mismatch repair
Gleason grading system
PARPi
aggressive variant prostate cancer
grade groups
immunotherapy
prostate cancer
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
11 Jul 2021
11 Jul 2021
Historique:
received:
28
06
2021
accepted:
07
07
2021
entrez:
24
7
2021
pubmed:
25
7
2021
medline:
25
7
2021
Statut:
epublish
Résumé
The 2021 novelties in prognostic and therapeutic tissue markers in patients with prostate cancer (PCa) can be subdivided into two major groups. The first group is related to prognostic markers based on morphological and immunohistochemical evaluations. The novelties in this group can then be subdivided into two subgroups, one involving morphologic evaluation only, i.e.,
Identifiants
pubmed: 34298683
pii: cancers13143471
doi: 10.3390/cancers13143471
pmc: PMC8307279
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Curr Drug Targets. 2015;16(2):103-14
pubmed: 25547910
N Engl J Med. 2012 Jan 12;366(2):141-9
pubmed: 22236224
JNCI Cancer Spectr. 2019 Nov 11;4(1):pkz095
pubmed: 32259017
BMC Cancer. 2018 Jan 2;18(1):8
pubmed: 29295717
Mod Pathol. 2015 Jan;28(1):128-137
pubmed: 24993522
Eur Urol. 2021 Jan;79(1):3-5
pubmed: 33189461
Ann Oncol. 2020 Sep;31(9):1119-1134
pubmed: 32593798
Mol Cancer Ther. 2021 Jun 22;:
pubmed: 34158347
Clin Cancer Res. 2014 Jun 1;20(11):2846-50
pubmed: 24727321
J Natl Compr Canc Netw. 2021 Feb 02;19(2):134-143
pubmed: 33545689
Arch Pathol Lab Med. 2021 Apr 1;145(4):461-493
pubmed: 32589068
Future Sci OA. 2019 Dec 05;6(1):FSO437
pubmed: 31915536
Cell. 2015 May 21;161(5):1215-1228
pubmed: 26000489
Cells. 2020 Jun 19;9(6):
pubmed: 32575429
Clin Cancer Res. 2019 Feb 1;25(3):928-936
pubmed: 30037818
Cells. 2020 Dec 24;10(1):
pubmed: 33374303
Int J Mol Sci. 2021 Feb 04;22(4):
pubmed: 33557050
Virchows Arch. 2019 Jul;475(1):77-83
pubmed: 31098801
Cells. 2019 Jan 11;8(1):
pubmed: 30642011
BMC Cancer. 2020 Jun 18;20(1):572
pubmed: 32552802
Am J Surg Pathol. 2020 Aug;44(8):e87-e99
pubmed: 32459716
Eur Urol. 2021 Feb;79(2):263-282
pubmed: 33039206
Cancers (Basel). 2021 Mar 26;13(7):
pubmed: 33810357
Cells. 2020 Apr 25;9(5):
pubmed: 32344931
Cells. 2020 Dec 10;9(12):
pubmed: 33321757
Nat Rev Nephrol. 2017 Dec;13(12):731-749
pubmed: 29081510
Annu Rev Genomics Hum Genet. 2019 Aug 31;20:293-307
pubmed: 30848956
J Clin Oncol. 2003 Jul 15;21(14):2673-8
pubmed: 12860943
Biomark Res. 2021 Feb 18;9(1):14
pubmed: 33602330
Eur J Cancer. 2021 Apr;147:74-83
pubmed: 33626496
Eur Urol. 2017 Nov;72(5):828-834
pubmed: 28818355
Future Oncol. 2020 Feb;16(5):75-80
pubmed: 31916449
Adv Anat Pathol. 2021 Jan;28(1):1-7
pubmed: 33027069
Expert Rev Anticancer Ther. 2016;16(4):433-40
pubmed: 27008205
Int J Environ Res Public Health. 2017 Mar 07;14(3):
pubmed: 28272371
Am J Surg Pathol. 2016 Feb;40(2):244-52
pubmed: 26492179
Int J Mol Sci. 2021 May 24;22(11):
pubmed: 34073818
Eur Urol. 2021 Feb;79(2):243-262
pubmed: 33172724
Arch Pathol Lab Med. 2020 Jan;144(1):18-23
pubmed: 31403335
Clin Cancer Res. 2021 Jun 18;:
pubmed: 34145028
J Clin Invest. 2018 Oct 1;128(10):4236-4242
pubmed: 30272580
J Extracell Vesicles. 2020 Mar 11;9(1):1736935
pubmed: 32284825
Virchows Arch. 2016 May;468(5):607-17
pubmed: 26861919
Prostate. 2018 Apr;78(5):401-407
pubmed: 29368341
Front Oncol. 2018 Dec 21;8:653
pubmed: 30622933
N Engl J Med. 2020 May 28;382(22):2091-2102
pubmed: 32343890
Expert Rev Mol Diagn. 2020 Feb;20(2):117-121
pubmed: 31933387
NPJ Digit Med. 2019 Jun 7;2:48
pubmed: 31304394
Clin Cancer Res. 2021 Jun 1;27(11):3094-3105
pubmed: 33558422
Cancer Treat Rev. 2016 Feb;43:27-35
pubmed: 26827690
Front Pharmacol. 2021 Jan 26;11:610601
pubmed: 33574757
Hum Mutat. 2012 May;33(5):887-94
pubmed: 22334387
Transl Androl Urol. 2021 Mar;10(3):1499-1505
pubmed: 33850784